Is There a Role for the Therapeutic Drug Monitoring of Colistin? An Overview

Autor:	Diego Jaimes, Julio César García, Maria Paula Avila, Rosa-Helena Bustos, Tatiana Pacheco, Sara Arias
Rok vydání:	2020
Předmět:	0301 basic medicine medicine.medical_specialty medicine.drug_class 030106 microbiology Antibiotics lcsh:Medicine lcsh:RS1-441 Pharmaceutical Science Multiresistant bacteria Nephrotoxicity lcsh:Pharmacy and materia medica 03 medical and health sciences therapeutic drug monitoring (tdm) 0302 clinical medicine Dose adjustment Drug Discovery polycyclic compounds Medicine In patient colistin 030212 general & internal medicine Intensive care medicine medicine.diagnostic_test business.industry Brief Report lcsh:R biochemical phenomena metabolism and nutrition multiresistant bacteria Therapeutic drug monitoring Colistin Molecular Medicine lipids (amino acids peptides and proteins) business medicine.drug
Zdroj:	Pharmaceuticals, Vol 13, Iss 3, p 42 (2020) Pharmaceuticals
ISSN:	1424-8247
DOI:	10.3390/ph13030042
Popis:	Colistin is used as a last-line antibiotic for the treatment of Gram-negative multiresistant bacteria. Due to its high nephrotoxicity, Therapeutic Drug Monitoring (TDM) is recommended for dose adjustment. We aimed to evaluate the available evidence of TDM in patients given colistin to treat Gram-negative infections. In this paper, we offer an overview, using an electronic search of the literature (published up to June 2019, without language restrictions) that compares the clinical outcomes and measurements of colistin TDM. Ultimately, the Therapeutic Drug Monitoring (TDM) of colistin in Plasma could prevent nephrotoxicity risk.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac14f5ee0a41120f5d3f9abe065c2c97 https://doi.org/10.3390/ph13030042 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.